跳至主要内容
临床试验/NCT00509873
NCT00509873已完成3 期

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Allergan0 个研究点目标入组 578 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
578
主要终点
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6

研究概览

简要总结

The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Year 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinically diagnosed with bacterial conjunctivitis

排除标准

  • Signs and/or symptoms of conjunctivitis for more than 96 hours
  • Signs and/or symptoms suggestive of fungal, viral, or allergic conjunctivitis
  • Clinical diagnosis of chlamydia in either eye

研究组 & 干预措施

Gatifloxacin 0.5% Eye Drops

Experimental

Gatifloxacin 0.5% Eye Drops

干预措施: Gatifloxacin 0.5% eye drops (Drug)

Placebo Eye Drops

Placebo Comparator

Placebo Eye Drops

干预措施: placebo eye drops (Drug)

结局指标

主要结局

Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6

时间窗: Day 6

Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).

次要结局

  • Percentage of Patients With Microbiological Cure at Day 6(Day 6)
  • Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6(Day 6)
  • Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6(Day 6)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验